Literature DB >> 1804652

Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration.

E Rey1, L Delaunay, G Pons, I Murat, M O Richard, C Saint-Maurice, G Olive.   

Abstract

Twelve children 1-5 y old were randomly assigned to receive midazolam 0.2 mg.kg-1 either by the intravenous (IV) or intranasal (IN) routes. After IN administration the rapid onset of absorption was observed (tmax 12 min). After both routes of administration the half-life was similar (2.2 h IN and 2.4 h IV). After IN administration the apparent plasma clearance and volume of distribution were about twice as high as after IV administration. The results are consistent with an estimated mean bioavailability of 55%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804652     DOI: 10.1007/BF00314967

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Dose dependent pharmacokinetics of midazolam.

Authors:  L D Bornemann; B H Min; T Crews; M M Rees; H P Blumenthal; W A Colburn; I H Patel
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Intramuscular midazolam for pediatric preanesthetic sedation: a double-blind controlled study with morphine.

Authors:  L Rita; F L Seleny; A Mazurek; S Y Rabins
Journal:  Anesthesiology       Date:  1985-11       Impact factor: 7.892

3.  The pharmacokinetics of rectal midazolam for premedication in children.

Authors:  C Saint-Maurice; C Meistelman; E Rey; C Esteve; D de Lauture; G Olive
Journal:  Anesthesiology       Date:  1986-11       Impact factor: 7.892

4.  Preanesthetic sedation of preschool children using intranasal midazolam.

Authors:  N C Wilton; J Leigh; D R Rosen; U A Pandit
Journal:  Anesthesiology       Date:  1988-12       Impact factor: 7.892

5.  The pharmacokinetics of midazolam in paediatric patients.

Authors:  K Payne; F J Mattheyse; D Liebenberg; T Dawes
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Midazolam kinetics.

Authors:  H Allonen; G Ziegler; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

7.  The pharmacokinetics of midazolam in man.

Authors:  M T Smith; M J Eadie; T O Brophy
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

8.  Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics.

Authors:  A A Holazo; M B Winkler; I H Patel
Journal:  J Clin Pharmacol       Date:  1988-11       Impact factor: 3.126

9.  Midazolam in paediatric anaesthesia.

Authors:  W H Cole
Journal:  Anaesth Intensive Care       Date:  1982-02       Impact factor: 1.669

Review 10.  Midazolam: pharmacology and uses.

Authors:  J G Reves; R J Fragen; H R Vinik; D J Greenblatt
Journal:  Anesthesiology       Date:  1985-03       Impact factor: 7.892

  10 in total
  24 in total

1.  Intranasal midazolam for febrile seizures. A step forward in treating a common and distressing condition.

Authors:  G Koren
Journal:  BMJ       Date:  2000-07-08

2.  Pharmacokinetics of midazolam in critically ill pediatric patients.

Authors:  M C Nahara; J McMorrow; P R Jones; D Anglin; R Rosenberg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

3.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

4.  A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing.

Authors:  R McGlone; T Fleet; S Durham; S Hollis
Journal:  Emerg Med J       Date:  2001-01       Impact factor: 2.740

Review 5.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

6.  Treatment of acute seizures: is intranasal midazolam a viable option?

Authors:  Lesley K Humphries; Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

Review 7.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 8.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method.

Authors:  E Fabre; S Chevret; J F Piechaud; E Rey; F Vauzelle-Kervoedan; P D'Athis; G Olive; G Pons
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

10.  Oral midazolam for voiding dysfunction in children undergoing voiding cystourethrography: a controlled randomized clinical trial.

Authors:  Anoush Azarfar; Mohammad Esmaeeili; Azadeh Farrokh; Ali Alamdaran; Aghilallah Keykhosravi; Mahboobe Neamatshahi; Alireza Hebrani; Yalda Ravanshad
Journal:  Nephrourol Mon       Date:  2014-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.